Zacks Research Issues Negative Outlook for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Zacks Research decreased their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.48) for the quarter, down from their prior estimate of ($1.47). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.

A number of other research analysts have also issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Wednesday. Barclays lowered their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Chardan Capital reissued a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $77.93.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $43.78 on Thursday. CRISPR Therapeutics has a 1 year low of $42.86 and a 1 year high of $91.10. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of -15.47 and a beta of 1.62. The stock’s fifty day moving average is $48.79 and its two-hundred day moving average is $51.21.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the company earned ($1.41) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CRSP. Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after buying an additional 743,075 shares during the last quarter. State Street Corp lifted its stake in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Farallon Capital Management LLC bought a new stake in CRISPR Therapeutics in the second quarter worth approximately $28,625,000. Marshall Wace LLP acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth $10,078,000. Finally, Private Advisor Group LLC raised its holdings in shares of CRISPR Therapeutics by 472.9% during the 2nd quarter. Private Advisor Group LLC now owns 77,627 shares of the company’s stock valued at $4,193,000 after purchasing an additional 64,076 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,382 shares of company stock worth $2,744,179. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.